🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Canada / NCT04299945
Recruiting Not applicable

Effects of Drinking Beetroot Juice on Exercise Performance in Patients With Fibrotic Interstitial Lung Disease

NCT04299945 · tracked via the Priya Life Science Canada tracker
Phase
Not applicable
Started
2024-08-07
Last updated
2026-05-18

Condition(s) studied

Interstitial Lung Disease

Investigational drug(s) / intervention(s)

concentrated beetroot juice (400mg of nitrate per serving)concentrated beetroot juice (trace amounts of nitrate per serving)

concentrated beetroot juice (400mg of nitrate per serving): Dietary nitrate supplementation includes consumption of two beverages daily for 7 consecutive days.

concentrated beetroot juice (trace amounts of nitrate per serving): Dietary placebo supplementation includes consumption of two beverages daily for 7 consecutive days.

Study summary

Exercise training as part of a structured pulmonary rehabilitation program is a key factor in improving quality of life and symptoms in people with interstitial lung disease (ILD). Optimal methods of exercise training are yet to be explored in ILD. Drinking beetroot juice, which is rich in nitrate, has been shown to improve exercise performance in a variety of groups, but its effects in ILD have not been tested. The purpose of this study is to determine if drinking nitrate-rich beetroot juice can improve exercise performance compared to drinking nitrate-free beetroot juice in people with ILD.

Eligibility

Sex
ALL
Min age
19 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * A multidisciplinary diagnosis of idiopathic pulmonary fibrosis (IPF), idiopathic fibrotic nonspecific interstitial pneumonia (NSIP), chronic hypersensitivity pneumonitis (HP), or unclassifiable ILD with a differential diagnosis that consists of the above diagnoses * Fibrosis on high resolution computed tomography (HRCT): honeycombing, reticulation, or traction bronchiectasis * Oxygen saturation ≥92% by pulse oximetry at rest while breathing room air * Clinically stable for the preceding 6 weeks * Can fluently read and write in English Exclusion Criteria: * Contraindication to exercise testing (e.g. significant cardiovascular, musculoskeletal, neurological disease) (see Table 4 from ERS/ATS consensus statement) * Other significant pulmonary or extra-pulmonary disease that, based on clinical assessment, could impair exercise capacity and/or oxygenation * FVC \<50% or DLCO \<25% * Use of prednisone \>10 mg/day for \>2 weeks within 3 months of the first study visit * Cardiac pacemaker or any metal or electronics inside of the body

Primary outcome measure(s)

Trial sites (2)

FacilityCityRegionStatus
Providence Health Care - St. Paul's Hosptial Vancouver British Columbia Recruiting
Vancouver Coastal Health Vancouver Canada Recruiting

More University of British Columbia trials in Canada

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04299945 on ClinicalTrials.gov ↗ ← All trials in Canada